Medical Advocates
Nevirapine (Viramune)
 
Journal Citations:  Adolescent/Adult
Indications

NVP/3TC                                    
NVP/EFV/DDI
 NVP/STV/3TC
 NVP/ZDV/DDI vs STV/DDI
 STV/DDI/NVP
 Miscellaneous  Combinations
 Post-Exposure Prophylaxis
Dosing
Adherence
Treatment Strategies
 Guidelines  
NVP Main Page Journal Main Page New/Newsworthy Home Page
Last Update:  December 26, 2008
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
NVP/3TC
           
  Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
 AAPS PharmSci 2000;2(1):E1
 Abstract 		 
NVP/EFV/DDI
           
  Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily
regimen for patients with HIV infection.
 Jordan WC, Jefferson R, Yemofio F, et al
J Natl Med Assoc. 2003 Dec; 95(12): 1152-7.
 Abstract
NVP/STV/3TC
           
 
Management of HIV-1 Infection With a Combination of Nevirapine, Stavudine, and Lamivudine:
A Preliminary Report on the Nigerian Antiretroviral Program.
 Idigbe EO, Adewole TA, Eisen G, et al  
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):65-69.
 Abstract
 
FULL-TEXT ARTICLE
 Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive
Patients Infected with HIV-1
 van Leth F , Phanuphak P Stroes  E , et al  
PLoS Medicine Vol 1, No 1
 Paper

FULL-TEXT PDF ARTICLE
 Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice.
 Yozviak JL, Eric Doerfler R, Woodward WC.
HIV Clin Trials 2001 Nov-Dec;2(6):474-476
 PDF Paper

Nevirapine or Efavirenz Combined with Two Nucleoside Reverse Transcriptase Inhibitors
Compared to HAART: A Meta-Analysis of Randomized Clinical Trials.
 Torre D, Tambini R, Speranza F, et al. 
HIV Clin Trials 2001 Mar-Apr;2(2):113-21
Abstract

Efficacy of nevirapine-based haart in hiv-1-infected, treatment-naive persons with high and
low baseline viral loads
 Raffi F, Reliquet V, Podzamczer D, Pollard RB.
 HIV Clin Trials 2001 Jul-Aug;2(4):317-22
Abstract

 
NVP/ZDV/DDI vs ZDV/DDI
           
  Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients
with HIV-1 infection. A randomized, double-blind, placebo-controlled trial.
 NIAID Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT, Hughes MD, Johnson VA, et al.
 Ann Intern Med 1996 Jun 15;124(12):1019-30
Abstract 		  
STV/DDI/NVP
           
  Immunologic response to antiretroviral treatment with combined stavudine, didanosine
and nevirapine.
 Reliquet V, Robillard N, Perre P, et al
Presse Med 2001 Jul 7-3;30(23):1143-7
Abstract 		 
Miscellaneous Combinations
           
 
FULL-TEXT ARTICLE
 Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients:
multicentric observation cohort.
 Li T, Dai Y, Kuang J,  et al
PLoS ONE. 2008;3(12):e3918.
Paper
 
FULL-TEXT PDF ARTICLE
 Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among
HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and
fluconazole.
 Manosuthi W, Athichathanabadi C, Uttayamakul S, et al
BMC Infect Dis. 2007 Mar 12;7(1):14
Paper
 
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful
first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing
efavirenz, nevirapine, or abacavir.
 Abgrall S, Yeni PG, Bouchaud O, et al
Clin Infect Dis. 2007 Jan 1;44(1):120-7.
 Abstract
 
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz,
or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
 Van Leth F, Phanuphak P, Ruxrungtham K, et al. 
Lancet. 2004 Apr 17;363(9417):1253-1263.
 Abstract

Nevirapine or Lamivudine plus Stavudine and Indinavir: Examples of 2-Class versus 3-Class
Regimens for the Treatment of Human Immunodeficiency Virus Type 1.
 Launay O, Gerard L, Morand-Joubert L
 Clin Infect Dis 2002 Nov 1;35(9):1096-105
 Abstract

Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside
reverse-transcriptase inhibitors.
Yozviak JL, Doerfler RE, Woodward WC.
Clin Infect Dis 2002 Feb 15;34(4):547-50
Abstract

FULL-TEXT PDF ARTICLE
 Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high
and low baseline viral loads.
 Raffi F, Reliquet V, Podzamczer D, Pollard RB, et al,
HIV Clin Trials 2001 Jul-Aug;2(4):317-22
 PDF Paper

 
Post-Exposure Prophylaxis
       
 
Tolerance of a Short Course of Nevirapine, Associated With 2 Nucleoside Analogues, in Postexposure
Prophylaxis of HIV.
Rey D, Partisani M, Hess-Kempf G, et al 
J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1454-6.
Abstract

Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis.
Puro V, Soldani F, De Carli G, et al 
AIDS. 2003 Sep 5;17(13):1988-90.
 Abstract
Dosing
       
 
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
 Moltó J, Valle M, Miranda C ,et al
J Antimicrob Chemother. 2008 Jun 30.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
 Cooper C, van Heeswijk R.
HIV Med. 2007 Jan;8(1):1-7.
 Abstract
Adherence
       
 
Home deliveries: Implications for adherence to nevirapine in a PMTCT programme in
rural Malawi.
 Kasenga F, Hurtig AK, Emmelin M.
AIDS Care. 2007 May;19(5):646-52.
 Abstract
Guidelines and Recommendations
United States      
United States
 
  FULL-TEXT REPORT
 Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
 US DHHS
 October 12, 2006
 Guidelines		  

 
NVP  Main Page Journal Main Page New/Newsworthy Home Page

Nevirapine Journal Data
Adolescent/Adult Indications